Back to results
US 2013/0095487 A1Published application
Interferon-Gamma Response as a Diagnostic Test for Persistent Chlamydial Infections
AssigneesUniversity of South Florida, Wayne State University, University Health Network
InventorsJohn D. Carter, Alan P. Hudson, Robert D. Inman
Life of this patent
Estimating the term…
Abstract
The present invention provides a non-invasive, sensitive, and convenient diagnostic test for persistent Chlamydial infection and diseases arising from persistent Chlamydial infection. The present invention also provides kits for diagnosis of persistent Chlamydial infection.
Claims20
A method of diagnosing persistent Chlamydial infection comprises:
- a) obtaining a biological sample from a subject, wherein the biological sample contains immune cells capable of producing IFN-γ;
- b) contacting the biological sample with a peptide antigen;
- c) determining a level of IFN-γ in the biological sample;
- and
- d) comparing the level of IFN-γ in the biological sample to a predetermined reference value;
- wherein the peptide antigen is derived from Chlamydial heat shock protein-60 (HSP-60) expressed during persistent infection;
- and
- wherein an elevated level of IFN-γ in the biological sample compared to the predetermined reference value indicates that the subject has persistent Chlamydial infection.
5 more elements
A kit for diagnosing persistent Chlamydial infection, wherein the kit comprises
- an antibody, apatamer, or binding agent that binds specifically to a peptide antigen molecule derived from a Chlamydial heat shock protein-60 selected from the group consisting of Chlamydia trachomatis (Ct) protein encoded by Ct604, Chlamydia trachomatis (Ct) protein encoded by Ct110, Chlamydia trachomatis (Ct) protein encoded by Ct849, Chlamydia trachomatis (Ct) protein encoded by Ct413, and Chlamydia trachomatis (Ct) protein encoded by Ct600;
- an application zone for receiving a blood sample;
- a labeling zone containing a binding agent that binds to IFN-γ or mRNA in the sample;
- and
- a detection zone where an IFN-γ-bound binding agent is retained to give a signal, wherein the signal given for a sample of a subject with the IFN-γ level greater than a control level is different from the signal given for a sample of a subject with the IFN-γ level lower than a control level.
2 more elements
Dependencies are inferred from the claim text.